NCT07875049Recruiting
Additional Effects of Flutter With Conventional Chest Physiotherapy on Peak Expiratory Flow Rate and Chest Expansion in Post CABG Patients With COPD
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
Flutter therapy is an oscillating positive expiratory pressure (OPEP) technique that combines positive expiratory pressure with airway oscillations to facilitate mobilization and clearance of respiratory secretions. Conventional chest physiotherapy includes deep breathing exercises, incentive spirometry, airway-clearance techniques, splinted coughing and early mobilization to promote lung expansion and secretion clearance. A total of 94 patients aged 40-70 years with mild-to-moderate COPD undergoing elective coronary artery bypass grafting (CABG) will be enrolled in this randomized controlled trial and will be randomly allocated into two groups, with 47 participants in each group. The intervention group will receive conventional chest physiotherapy combined with Flutter therapy, while the control group will receive conventional chest physiotherapy alone. Both groups will receive supervised treatment for 5 consecutive postoperative days, with 3 sessions per day, resulting in 15 treatment sessions. Baseline assessment will be performed on postoperative day 1 before commencement of the intervention, and post-intervention assessment will be conducted on postoperative day 5. The study will compare the effects of Flutter-assisted conventional chest physiotherapy versus conventional chest physiotherapy alone on postoperative peak expiratory flow rate, chest expansion and airway clearance.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 7 Oct 2026
- Start date
- 11 Feb 2026
- Primary completion date
- 20 Dec 2026
- Lead sponsor
- Foundation University Islamabad
- Diseases
- COPD
- NCT number
- NCT07875049
What you commit to
- Study type: Interventional
- Planned participants: 84
- From 11 Feb 2026 to the primary completion date, 20 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications positive expiratoey pressure (PEP) therapy (e.g, untreated pneumothorax, hemoptysis or recent esophageal surgery).
Other illness
- Patients with severe COPD or intersitial lung disease
- Patients with active infections, malignancy.
- Patients with severe or uncontrolled comorbidities(e.g; renal failure).
Other
- Patients undergoing emergency CABG or revision/repeat CABG procedure
- Hemodynamically unstable patients post-operatively.
- Patients with neurological, musculoskeletal or cognitive impairments.
- Patients in BiPAP.
Who the study is looking for
- Adults aged 40-70 years undergoing elective CABG
- Pre-existing COPD (mild- moderate), clinically diagnosed COPD
- Early post-operative (24-72 hrs.), extubated and hemodynamically stable
- No mechanical ventilation beyond 24 hrs., stable vitals (HR: 60-100bpm, SBP :110-130mmhg), no vasopressors.
- Follow commands, provide consent and perform assessments.
Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Foundation University Islamabad Coordinator of this site? Confirm its status | Rawalpindi | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.